Biomarin Pharmaceutical
(NASDAQ:BMRN)
$103.02
At close: Dec 1(Delayed 15-Minutes)
Get Real Time Here
$103.02
PreMarket: 4:57PM EDT
Day Range- - -52 Wk Range70.73 - 103.06Open / Close- / -Float / Outstanding185M / 185.8M
Vol / Avg.- / 1.4MMkt Cap19.1BP/E239.5850d Avg. Price88.15
Div / Yield-Payout Ratio-Total Float185MEPS-0.04

Biomarin Pharmaceutical Stock (NASDAQ:BMRN), Quotes and News Summary

Biomarin Pharmaceutical Stock (NASDAQ: BMRN) stock price, news, charts, stock research, profile.

Loading...
Day Range- - -52 Wk Range70.73 - 103.06Open / Close- / -Float / Outstanding185M / 185.8M
Vol / Avg.- / 1.4MMkt Cap19.1BP/E239.5850d Avg. Price88.15
Div / Yield-Payout Ratio-Total Float185MEPS-0.04
Seeking Alpha - Nov 15, 2022, 11:15PM
Seeking Alpha - Oct 25, 2022, 5:35PM
Seeking Alpha - Oct 20, 2022, 12:30AM
Seeking Alpha - Oct 20, 2022, 12:30AM
Seeking Alpha - Oct 15, 2022, 7:01PM
Sector: Health Care.Industry: Biotechnology
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) is poised to potentially launch in the 2022-23 timeframe.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-02-22
REV
Q3 2022Est.ActualSurprise
EPS-0.010-0.040 -0.0300
REV518.910M505.344M-13.566M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Biomarin Pharmaceutical (BMRN) stock?

A

You can purchase shares of Biomarin Pharmaceutical (NASDAQ: BMRN) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Biomarin Pharmaceutical's (BMRN) competitors?

Q

What is the target price for Biomarin Pharmaceutical (BMRN) stock?

A

The latest price target for Biomarin Pharmaceutical (NASDAQ: BMRN) was reported by Jefferies on Tuesday, November 29, 2022. The analyst firm set a price target for 120.00 expecting BMRN to rise to within 12 months (a possible 16.48% upside). 17 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Biomarin Pharmaceutical (BMRN)?

A

The stock price for Biomarin Pharmaceutical (NASDAQ: BMRN) is $103.02 last updated December 1, 2022, 9:00 PM UTC.

Q

Does Biomarin Pharmaceutical (BMRN) pay a dividend?

A

There are no upcoming dividends for Biomarin Pharmaceutical.

Q

When is Biomarin Pharmaceutical (NASDAQ:BMRN) reporting earnings?

A

Biomarin Pharmaceutical’s Q4 earnings are confirmed for Wednesday, February 22, 2023.

Q

Is Biomarin Pharmaceutical (BMRN) going to split?

A

There is no upcoming split for Biomarin Pharmaceutical.

Q

What sector and industry does Biomarin Pharmaceutical (BMRN) operate in?

A

Biomarin Pharmaceutical is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.